New drug cocktail targets tough cancers in early trial
NCT ID NCT03065062
First seen Sep 30, 2025 · Last updated Jun 21, 2026 · Updated 38 times
Summary
This early-phase study tests a combination of two targeted drugs, palbociclib and gedatolisib, in people with advanced lung, pancreatic, head & neck, or other solid tumors that have stopped responding to standard treatments. The main goal is to find the safest dose and look for early signs that the drugs can control tumor growth. About 75 participants will take part, and the trial is currently on hold.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Palbociclib and Gedatolisib (two targeted cancer drugs)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial, so the main goal is just finding a safe dose. It is too soon to know if the combination will actually shrink tumors or improve survival, and side effects are expected.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.